New Four-Pronged antibody takes aim at lupus

NCT ID NCT06857214

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This phase 1 trial tests a new drug called GNC-038, a tetra-specific antibody designed to target multiple pathways involved in lupus. The study includes adults with moderate to severe lupus who are on stable standard treatment. Researchers are evaluating the drug's safety, tolerability, and how the body processes it, while also looking for early signs of effectiveness in controlling the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GNC-038 (a tetra-specific antibody)
What this could lead to
If successful, this could point toward a new treatment option for people with moderate to severe lupus, potentially offering better disease control with fewer side effects.
What could go wrong
This is an early phase 1 trial with only 84 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to improve lupus symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.